Novo accelerates launch plans for oral semaglutideNovo Nordisk has said it is accelerating launch preparations for its new diabetes pill semaglutide, after investing in Share XNovo accelerates launch plans for oral semaglutidehttps://pharmaphorum.com/news/novo-accelerates-launch-plans-for-oral-semaglutide/
Novo begins R&D tie-up with AI biotech e-TherapeuticsNovo Nordisk has signed a deal with UK biotech e-Therapeutics to use its AI-based drug discovery technology to Share XNovo begins R&D tie-up with AI biotech e-Therapeuticshttps://pharmaphorum.com/news/novo-begins-rd-tie-up-with-ai-biotech-e-therapeutics/
Novo Nordisk’s diabetes pill clears cardiac safety hurdleNovo Nordisk is set to file its daily semaglutide type 2 diabetes pill after it cleared a phase Share XNovo Nordisk’s diabetes pill clears cardiac safety hurdlehttps://pharmaphorum.com/news/novos-diabetes-pill-clears-cardiac-safety-hurdle-filings-to-follow/
Gene therapy firm BioMarin stages haemophilia musicalBioMarin Pharmaceutical has put on a stage musical to raise awareness about haemophilia, and determine whether creative expression Share XGene therapy firm BioMarin stages haemophilia musicalhttps://pharmaphorum.com/news/gene-therapy-firm-biomarin-stages-haemophilia-musical/
Novo Nordisk staff cull swells to 1,300Novo Nordisk has raised the number of staff it will shed this year in order to invest more Share XNovo Nordisk staff cull swells to 1,300https://pharmaphorum.com/news/novo-nordisk-staff-cull-swells-to-1300/
AZ to continue with investment freeze following ‘no deal’ BrexitAstraZeneca will keep manufacturing investments in Britain on hold if the UK’s negotiations with Brussels fail to provide Share XAZ to continue with investment freeze following ‘no deal’ Brexithttps://pharmaphorum.com/news/az-to-continue-with-investment-freeze-following-no-deal-brexit/
Novo Nordisk poaches AZ’s Helfgott to run Biopharm businessNovo Nordisk has poached a top executive from AstraZeneca, tasking Ludovic Helfgott to lead development of its haemophilia Share XNovo Nordisk poaches AZ’s Helfgott to run Biopharm businesshttps://pharmaphorum.com/news/novo-nordisk-poaches-azs-helfgott-to-run-biopharm-business/
Lilly unveils promising data from dual-action diabetes drugEli Lilly’s investigational diabetes drug has shown early promise as a possible aid to overcoming obesity in trial Share XLilly unveils promising data from dual-action diabetes drughttps://pharmaphorum.com/news/lilly-diabetes-unveils-promising-data-from-dual-action-diabetes-drug/
Novo to market ‘connected’ insulin pens next yearNovo Nordisk is to launch “connected” insulin pens, responding for demands from patients for devices able to communicate Share XNovo to market ‘connected’ insulin pens next yearhttps://pharmaphorum.com/news/novo-to-market-connected-insulin-pens-next-year/
